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Effect of chaetomellic acid on hematocrit, urine specific gravity 
and urinary volume values in a rat model of renal mass reduction 
Introduction 
 
The development of chronic renal disease has been frequently investigated using the 5/6 
renal mass reduction model. Along time, the animals develop a syndrome of systemic and 
glomerular hypertension, hypertrophy, hyperfiltration, proteinuria, and progressive 
glomerular and interstitial fibrosis of the initially normal remnant nephrons. Due the clinical 
relevance of this problem, some therapeutic and experimental options have evolved over 
the time to improve the recovery of renal injury or to successfully prevent this disease. One 
of drugs used in experimental studies is chaetomellic acid (CA) a potent and highly specific 
inhibitor of ras farnesyl-protein transferase that seems to reduce both functional and 
histological damage in uninephrectomized rats subjected to renal ischaemia-reperfusion 
injury.  
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Objective 
 
The aim of this work was to evaluate the effect of chronic treatment with CA on hematocrit, 
urine specific gravity and urinary volume in a model of renal mass reduction. 
Results and Discussion 
 
We observed that animals from SO groups showed a higher hematocrit (Figure 1) and urine 
specific gravity (Figure 3), and a lower urinary volume (Figure 2) than animals from RMR 
groups (p<0.05). These results are in accordance with studies of this renal mass reduction 
model previously published. Animals from RMR group with treatment showed a higher 
urine specific gravity than animals from RMR group without treatment (p<0.05). In other 
groups we did not observe differences between treated and no treated animals. 
Figure 1 - 
Table 1 -   
Material and methods 
 
Fifty-two male Wistar rats were subjected to 5/6 nephrectomy (RMR) or sham-operated 
(SO). Surgical reduction of renal mass was performed under anesthesia with ketamin at 
70mg/Kg (Imalgene® 1000, Merial S.A.S., Lyon, France)  and xilazin at 10mg/Kg (Rompum® 
2%, Bayer S.A., Kiel, Germany). Animals from RMR groups were subjected to right 
uninephrectomy and removal of both poles of the left kidney and rats from sham-operated 
groups were submitted to the same surgical technique without reduction of renal mass. 
One week after surgery, rats have been placed in four experimental groups: RMR rats 
without treatment (n=13); RMR rats treated with CA (n=13); SO rats without treatment 
(n=13); SO rats treated with CA (n=13). CA was intraperitoneally administered in a dose of 
0.23 µg/Kg three times a week for three months. Once-a-month were collected blood and 
urine samples to determine haematocrit value, urinary volume and urine specific gravity. 
Conclusion 
 
These results suggest that three months of treatment with CA does not have a beneficial 
effect on hematocrit, urine specific gravity and urinary volume. However, these are 
preliminary data that warrant a larger scale study. 
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Figure 1. Determination of haematocrit (%) in groups: Sham without 
treatment, Sham with treatment, RMR without treatment and RMR 
with treatment.  
Figure 2. Measurement of urinary volume (mL) in groups: Sham 
without treatment, Sham with treatment, RMR without treatment 
and RMR with treatment.  
Figure 3. Determination of urine specific gravity in groups: Sham 
without treatment, Sham with treatment, RMR without treatment 
and RMR with treatment.  
